The trial, which enrolled 122 patients
with refractory or relapsed colorectal cancer, also failed to meet
the secondary goal of showing improved response to the drug
tivantinib.
Several months ago tivantinib failed
for lung cancer. This time it failed in colon cancer. And tivantinib
is of course targeted drug: ArQule's
lead product, tivantinib (ARQ 197), is designed to block the activity
of a molecule known as c-Met that plays multiple key roles in human
cancer
No comments:
Post a Comment